Abstract
Many prognostic models for cardiovascular risk can be used to estimate aspirin's absolute benefits, but few bleeding risk models are available to estimate its likely harms. To develop prognostic bleeding risk models among persons in whom aspirin might be considered for the primary prevention of cardiovascular disease (CVD). Prospective cohort study. New Zealand primary care. The study cohort comprised 385 191 persons aged 30 to 79 years whose CVD risk was assessed between 2007 and 2016. Those with indications for or contraindications to aspirin and those who were already receiving antiplatelet or anticoagulant therapy were excluded. For each sex, Cox proportional hazards models were developed to predict major bleeding risk; participants were censored at the earliest of the date on which they first met an exclusion criterion, date of death, or study end date (30 June 2017). The main models included the following predictors: demographic characteristics (age, ethnicity, and socioeconomic deprivation), clinical measurements (systolic blood pressure and ratio of total-high-density lipoprotein cholesterol), family history of premature CVD, medical history (smoking, diabetes, bleeding, peptic ulcer disease, cancer, chronic liver disea...Continue Reading
References
Jan 1, 1991·American Heart Journal·K M AndersonW B Kannel
Dec 31, 1997·BMJ : British Medical Journal·D E Grobbee, A W Hoes
Jun 6, 2003·European Heart Journal·R M ConroyUNKNOWN SCORE project group
Sep 13, 2005·Social Science & Medicine·Clare SalmondCharles Waldegrave
Aug 5, 2006·The American Journal of Medicine·Kenneth R McQuaid, Loren Laine
Jun 25, 2008·BMJ : British Medical Journal·Julia Hippisley-CoxPeter Brindle
Jun 2, 2009·Lancet·UNKNOWN Antithrombotic Trialists' (ATT) CollaborationAlberto Zanchetti
Jun 19, 2012·JAMA : the Journal of the American Medical Association·Giorgia De BerardisAntonio Nicolucci
Jul 6, 2012·European Journal of Preventive Cardiology·UNKNOWN Fifth Joint Task Force of the European Society of CardiologyUNKNOWN European Heart Network
Aug 21, 2012·The Medical Journal of Australia·David W JohnsonUNKNOWN Australasian Creatinine Consensus Working Group
Mar 19, 2013·BMC Medical Research Methodology·Patrick Royston, Douglas G Altman
Nov 14, 2013·Circulation·David C GoffGordon F Tomaselli
Apr 2, 2014·Journal of the American College of Cardiology·Craig T JanuaryClyde W Yancy
Jul 30, 2014·BMJ : British Medical Journal·Julia Hippisley-Cox, Carol Coupland
Jan 7, 2015·Annals of Internal Medicine·Gary S CollinsKarel G M Moons
Jan 7, 2015·Annals of Internal Medicine·Karel G M MoonsGary S Collins
Nov 23, 2015·International Journal of Cardiology·Prasad S NishtalaSarah N Hilmer
Apr 12, 2016·Annals of Internal Medicine·Evelyn P WhitlockCorinne V Evans
Apr 12, 2016·Annals of Internal Medicine·Kirsten Bibbins-Domingo, UNKNOWN U.S. Preventive Services Task Force
May 5, 2016·Circulation·Jennifer G Robinson, Kausik Ray
May 26, 2017·BMJ : British Medical Journal·Julia Hippisley-CoxPeter Brindle
May 8, 2018·Lancet·Romana PylypchukRod Jackson
Jun 28, 2018·JAMA : the Journal of the American Medical Association·Vanessa SelakSue Wells
Aug 28, 2018·The New England Journal of Medicine·UNKNOWN ASCEND Study Collaborative GroupJane Armitage
Aug 31, 2018·Lancet·J Michael GazianoUNKNOWN ARRIVE Executive Committee
Sep 18, 2018·The New England Journal of Medicine·John J McNeilUNKNOWN ASPREE Investigator Group
Citations
Nov 26, 2019·Cardiology in Review·Jonathan D CicciAnthony J Mazzella
Sep 24, 2019·Circulation·Guillaume Marquis-GravelW Schuyler Jones
Feb 26, 2019·Annals of Internal Medicine·Evelyn P Whitlock, Eric S Johnson
Sep 14, 2020·Annals of Surgical Oncology·Domenico TamburrinoMassimo Falconi
Oct 21, 2020·Heart·Tamar I de Vries, Frank L J Visseren
Oct 29, 2020·JAMA Cardiology·Ezimamaka AjufoAmit Khera
Nov 23, 2020·The American Journal of Cardiology·Osama DasaThomas A Pearson
Apr 25, 2021·BMC Cardiovascular Disorders·Wai Chung TseVanessa Selak
May 23, 2020·Journal of the American College of Cardiology·Leslie ChoUNKNOWN ACC CVD Womens Committee Members